AnodyneWiki

Nitroglycerine

NG
Nitroglycerine
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass227.09 g/mol [1]
AppearanceVISCOUS LIQUID [1]
TasteSweet, burning taste [1]
Density1.6 (NIOSH, 2024) - Denser than water; will sink [1]
Melting point56 °F (NIOSH, 2024) [1]
Boiling pointBegins to decompose at 122-140 °F (NIOSH, 2024) [1]
DecompositionBegins to decompose at 50-60 °C, appreciable volatile at 100 °C evolves nitrous yellow vapors at 135 °C. [1]
Solubility0.1 % (NIOSH, 2024) [1]
Predicted LogP1.6 [1]
Structural Identifiers
[]
Molecular formulaC3H5N3O9
IUPAC name1,3-dinitrooxypropan-2-yl nitrate
SMILESC(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-]
InChIInChI=1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2
InChIKeySNIOPGDIGTZGOP-UHFFFAOYSA-N
CAS number55-63-0
UNIIG59M7S0WS3
PubChem CID4510

Nitroglycerine (also known as Glyceryl trinitrate, Trinitroglycerin, Nitrostat, Nitroglycerol, Glycerol trinitrate, Trinitroglycerol, Nitro-dur, Minitran, Trinitrin or Nitronet).

Chemistry

 []

Nitroglycerine is achiral.

Nitroglycerine matches Lipinski's rule of five.

Pharmacology

Mechanism of action []

Nitroglycerin is converted by mitochondrial aldehyde dehydrogenase in smooth muscle cells to nitric oxide (NO), a potent vasodilator. NO activates the enzyme guanylate cyclase, which converts guanosine triphosphate (GTP) to cyclic guanosine 3',5'-monophosphate (cGMP) in vascular smooth muscle and other tissues. cGMP is an endogenous vasodilator of vascular smooth muscle: it causes protein kinase-dependent phosphorylation and activates downstream cascades that promote relaxation and increased blood flow in veins, arteries and cardiac tissue. An _in vitro_ study using mouse aorta suggests that nitric oxide, an active metabolite of nitroglycerin, targets the natriuretic peptide receptors. [1]

Medical side effects []

103 side effects listed on drug labels in (nitroglycerin).

  • Headache
  • Throbbing headache
  • Nausea
  • Vomiting
  • Dizziness
  • Syncope
  • Hypotension
  • Hypotensive
  • Shock
  • Collapse
  • Loss of consciousness
  • Dermatitis contact
  • Allergic contact dermatitis
  • Pruritus
  • Application site erythema
  • Angina pectoris
  • Angina unstable
  • Dermatitis atopic
  • Hypersensitivity
  • Flushing
  • Orthostatic hypotension
  • Tachycardia
  • Reflex tachycardia
  • Dermatitis exfoliative
  • Abdominal pain
  • Abdominal colic
  • Gastrointestinal pain
  • Anaphylactic shock
  • Anaphylactoid reaction
  • Angioedema
  • Arrhythmia
  • Asthenia
  • Mental disorder
  • Coma
  • Infection
  • Confusional state
  • Feeling abnormal
  • Cyanosis
  • Drug eruption
  • Fixed drug eruption
  • Somnolence
  • Dyspnoea
  • Eczema
  • Dermatitis
  • Rash
  • Body temperature increased
  • Gastrointestinal disorder
  • Breath odour
  • Atrioventricular block
  • Cardiac disorder
  • Immune system disorder
  • Ischaemia
  • Renal failure acute
  • Mediastinal disorder
  • Methaemoglobinaemia
  • Nervous system disorder
  • Pallor
  • Palpitations
  • Paraesthesia
  • Pharyngitis
  • Rhinitis
  • Stomatitis
  • Hyperhidrosis
  • Sweating increased
  • Erythema
  • Redness
  • Urticaria
  • Angiopathy
  • Vascular headache
  • Vasodilation procedure
  • Vertigo
  • Burning sensation
  • Agitation
  • Oedema peripheral
  • Application site reaction
  • Diarrhoea haemorrhagic
  • Intracranial pressure increased
  • Skin disorder
  • Hyperventilation
  • Tachypnoea
  • Immobile
  • Respiratory rate decreased
  • Bradycardia
  • Pulse rate decrease marked
  • Clonic convulsion
  • Drug tolerance
  • Swollen tongue
  • Vision blurred
  • Rash generalised
  • Withdrawal hypertension
  • Application site irritation
  • Paralysis
  • Hypovolaemia
  • Visual impairment
  • Skin reaction
  • Menopausal symptoms
  • Hot flush
  • Hypoxia
  • Infestation
  • Application site pruritus
  • Chest discomfort
  • Cerebral ischaemia
  • Glucose-6-phosphate dehydrogenase deficiency

Indications

  • Acute myocardial infarction
  • Acute pulmonary oedema
  • Anal fissure
  • Angina pectoris
  • Anginal attack
  • Arteriospasm coronary
  • Cardiac failure congestive
  • Cardiac index
  • Cerebrovascular accident
  • Chronic anal fissure
  • Coronary artery disease
  • Coronary heart disease
  • Discomfort
  • Exercise induced angina
  • Haemorrhoids
  • Hypertension
  • Hypotension
  • Intraoperative hypotension
  • Left ventricular failure
  • Myocardial infarction
  • Nephropathy
  • Pain
  • Prinzmetal angina
  • Stable angina pectoris
  • Tachycardia
  • Tension
  • Vascular resistance
  • Vascular resistance systemic
  • Vasodilation
  • Ventricular extrasystoles

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 4510, Nitroglycerine. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/4510
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Nitroglycerine. UNII: G59M7S0WS3. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/G59M7S0WS3

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 20:00:41
drugspromissing (no DrugsPRO reagent data)2026-11-20 20:00:37
erowidmissing (no Erowid substance of that name)2026-11-20 20:00:37
gsrsok2026-11-20 20:00:37
hmdbmissing (hmdb.ca refused automated access to HMDB0014865)2026-11-20 20:00:37
keggok2026-11-20 20:00:41
pubchemok2026-11-20 20:00:36
redditmissing (no r/tripreports posts mention it)2026-11-20 20:00:37
siderok2026-11-20 20:00:37
structureok2026-11-20 20:00:37
wikipediamissing (no Wikipedia article with a drug infobox)2026-11-20 20:00:37